Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies

Objectives: Clinical benefits of immune-checkpoint blockade (ICB) versus standard chemotherapy have been established in unselected non-small cell lung cancer (NSCLC). However, the response to ICB therapy among patients is heterogeneous in clinical practice. Materials and Methods: We retrospectively...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Ma, Si-Cong, Tang, Xin-Ran, Long, Li-Li, Bai, Xue, Zhou, Jian-Guo, Duan, Zhi-Jiao, Wang, Jian, Fu, Qiang John, Zhu, Hong-Bo, Guo, Xue-Jun, Zhang, Yan-Pei, Guo, Ze-Qin, Wu, De-Hua, Dong, Zhong-Yi
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078693/
https://ncbi.nlm.nih.gov/pubmed/33996262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1909296
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars